vincristine

P2, N=66, Not yet recruiting, Ou Bai, MD/PHD

P2, N=120, Not yet recruiting, BeBetter Med Inc

P2, N=40, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Mar 2027 --> Sep 2029 | Trial primary completion date: Mar 2026 --> Mar 2028

P2, N=24, Recruiting, University of California, Davis | Trial primary completion date: Feb 2026 --> Oct 2026

P3, N=236, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Mar 2027 --> Mar 2026

Due to the diagnostic complexity, he was treated as having a non-Hodgkin lymphoma-like entity with R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) Although UCD is typically considered curable with surgical resection, this case demonstrates that, in rare cases, it can progress to lymphoma, specifically NLPHL. This case illustrates that even localized forms of UCD may be associated with subsequent lymphoid malignancy, emphasizing the importance of continuous clinical surveillance and a multidisciplinary approach to management. Histopathological reassessment of new lesions is crucial, and clinicians should consider the possibility of malignant transformation in patients with a history of UCD to ensure accurate diagnosis and timely treatment.

She underwent therapy with rituximab, methotrexate, procarbazine, and vincristine followed by high-dose cytarabine, achieving temporary remission; however, relapse occurred 1 month after consolidation therapy. This case also suggests a potential therapeutic role for tirabrutinib in early-relapsing LC. https://thejns.org/doi/10.3171/CASE26337.

P3, N=330, Recruiting, Universitt des Saarlandes | Trial primary completion date: Apr 2028 --> Feb 2029

P2, N=174, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2028 --> Feb 2027

Systemic chemotherapy with vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide was initiated, resulting in tumor shrinkage. To the best of our knowledge, this is the first reported case of BCS treated with CIRT. This case demonstrates that CIRT can achieve durable local control and suggests that it may represent a promising treatment option for BCS when surgical resection is challenging.

The standard treatment for cTVT is chemotherapy, primarily based on vincristine...Silver nanoparticles reduced with β-D-glucose induce cell death in cTVT cells without triggering an immunogenic response. These findings suggest that this nanomaterial may represent a promising novel therapeutic approach in veterinary oncology.

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.